Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639645 | 0.85 | ESR1 (0.44) | ESR1LTA4H | |
| SCHEMBL4639760 | 0.85 | ESR1 (0.45) | ESR1LTA4HLMNA | |
| SCHEMBL4639651 | 0.85 | ESR1 (0.42) | ESR1LMNAMAPTTP53VKORC1 | |
| SCHEMBL4640167 | 0.83 | ESR1 (0.57) | ESR1 | |
| SCHEMBL4640636 | 0.82 | ESR1 (0.45) | ESR1LTA4HVKORC1 | |
| SCHEMBL6152326 | 0.80 | CYP19A1 (0.51) | ESR1 | |
| SCHEMBL4639556 | 0.77 | ESR1 (0.42) | ESR1LTA4H | |
| SCHEMBL4639644 | 0.77 | LTA4H (0.45) | ESR1LTA4HTP53CHEK2 | |
| SCHEMBL4639606 | 0.77 | ESR1 (0.41) | ESR1LTA4H | |
| SCHEMBL14459770 | 0.73 | ESR1 (0.55) | ESR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667999-A4 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7247646-B2 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1667999-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050137231-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-06-23 | — | — | US | disclosed |
| WO-2005028472-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137231-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | ESR1, ESR2, ESRRG | ESR1 1/4885LTA4H 2205/4885LMNA 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.